Phase 3 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have a confirmed diagnosis of CLL/SLL (a type of blood cancer) with active disease that doctors have clearly documented as needing treatment to begin.
• People who have at least one measurable sign of disease burden (confirm with trial site for specific measures).
• People whose general physical ability and daily functioning falls within an acceptable range, as assessed by a standard medical scale, within 7 days before being enrolled in the trial.
• People who are able to swallow and keep down oral (tablet or capsule) medication.
• People who are hepatitis B surface antigen positive may be considered, provided they have been on hepatitis B antiviral treatment for at least 4 weeks and the virus is undetectable in their blood before enrollment.
• People with a history of hepatitis C infection may be considered, provided the hepatitis C virus is undetectable in their blood at the screening stage.
• People living with HIV may be considered, provided they meet all other eligibility criteria.

Who may not be able to join:

• People with a currently active hepatitis B or hepatitis C infection.
• People with a digestive system condition that could affect how the body absorbs medication.
• People whose CLL/SLL has transformed into a more aggressive cancer type (Richter Transformation), or whose cancer has spread to the central nervous system (brain and spinal cord).
• People who have had a serious AIDS-related opportunistic infection within the 12 months before screening.
• People with significant heart or blood vessel disease.
• People who have a known allergy or medical reason to avoid nemtabrutinib, ibrutinib, acalabrutinib, or any of the inactive ingredients in these medicines.
• People with a history of severe bleeding disorders.
• People with another cancer that is still progressing or has required active treatment within the past 2 years.
• People who have previously received any systemic (whole-body) anti-cancer treatment for CLL/SLL.
• People currently taking certain medications that interact with the study drugs, including specific drug transporters or liver enzyme pathways (confirm specific medications with the trial site).
• People who received radiation therapy within 2 weeks before starting the study, or who still have side effects from radiation that require steroid treatment.
• People who received a live or live-attenuated vaccine within 30 days before the first dose of the study treatment (non-live/killed vaccines are permitted).
• People who have taken part in another clinical trial or used an experimental medical device within 4 weeks before starting the study.
• People with an active infection that requires systemic treatment, including intravenous antibiotics, during the screening period.
• People who have not fully recovered from major surgery, or who still have ongoing complications from surgery.

Important: Always verify eligibility with the trial site directly before applying.